Allergan and Endo Pharma Under StockCall's Microscope: Drug Companies Restructure Their Businesses

LONDON, February 25, 2013 /PRNewswire/ --

The drug manufacturing sector is always on the run. While some companies are getting new product approvals, others are being targeted for a takeover bid. Allergan Inc. (NYSE: AGN) is looking to perform better this year with new FDA approval for its breast implants. Endo Health Solutions Inc. (NASDAQ: ENDP), on the other hand, is on the verge of being acquired. Apart from this, the company's stock is also being lapped up by hedge funds, indicating a good future for the stock. Overall, the sector looks promising. StockCall has released full comprehensive research on Allergan and Endo Pharmaceuticals and these free technical analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Endo Health Solutions Inc. Inks Deal with GVK Biosciences

Endo Health Solutions Inc. is currently rumored to be the target of a takeover bid. The company stock lost 20 percent of its value in the past 52 weeks and now its largest shareholder wants the company to find itself a buyer. Any such sale is likely to be made at a premium to the company's current market price and hence will bring additional value to its shareholders. Register today and access the free research on Endo Pharmaceuticals Holdings Inc. at

http://www.StockCall.com/ENDP022513.pdf

Endo Health Solutions Inc. recently provided conservative estimates for its pain drug, Opana ER. The cut in estimates was mainly made due to the introduction of a generic version of the drug. However, it seems that the company had overestimated the negative impact of the generic drug. However, currently the bigger story about the company is its potential to be a takeover target. It is rumored that the company may be acquired by Valeant Pharmaceuticals or Warner Chilcott.

Even if there is no sale, Endo Health Solutions Inc. is firmly planning for growth as it inked a new deal with GVK Biosciences for developing and marketing new clinical drugs. The stock is also being picked up by Steve Cohen's SAC Capital Advisors which now has 4.6 million shares stake in the company. Hedge Fund D.E. Shaw also has a stake in the company.

Allergan Inc. May Sell Obesity Unit

Allergan Inc. is scaling new highs as the stock surpassed its previous 52-week high. The company also paid 5 cents per share in dividend. It also received the FDA approval for its new breast implants. On the growth front, the company acquired MAP Pharmaceuticals and the company is expected to gain foothold with this new acquisition. The company will augment its migraine portfolio with this acquisition. Allergan Inc. is looking to restructure its business. So, along with acquisitions, it also plans to dispose of some of its units. The company may look into selling its obesity units. Free technical analysis on Allergan Inc. available by signing up at

http://www.StockCall.com/AGN022513.pdf

Allergan Inc. also recently announced its fourth quarter results, and beat consensus estimates by announcing $1.21 per share EPS. Its revenue for the quarter stood at $1.51 billion. As for fiscal 2013, the company expects its earnings to be in the range of $4.75 and $4.83 while its full year sales are expected to remain between $5.99 billion and $6.29 billion. The company stock is up 23 percent in the past 52 weeks and on the back of its good outlook, it is expected to keep performing well.

Allergan Inc. currently draws a big chunk of its revenue from its Botox products and it is a market leader in the segment. The company stock is expected to perform better in the future with its new business restructuring program.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com